Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,241.9
-38.2 (-1.16%)

 

  • STI Straits Times Index
    3,241.9
    -38.2 (-1.16%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,591.8
    2.9 (0.18%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,262.6
    -533.3 (-1.85%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,074.3
    -21.4 (-0.69%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,889.3
    -194.2 (-0.81%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,245.0
    -
    Index delayed 10 minutes
  • KOR KOSPI
    2,250.4
    -12.2 (-0.54%)
    Index delayed 20 minutes
  • XAO XAO
    7,163.8
    -32.5 (-0.45%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 616.6M
  • Value: 243.7M
  • Rise: 45
  • Fall: 186
  • Unch: 588

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
DISA0.004+0.001
Medtecs Intl0.064+0.012
Ntegrator Intl0.014-0.001
Jiutian Chemical0.022-
ThaiBev0.820-0.030
YZJ Shipbldg SGD1.110-0.030
Healthway Med0.034+0.006
AusGroup^0.046-0.002
Rex Intl0.192-0.003
MarcoPolo Marine0.024-0.001

World Indices

World Indices
Name Last Change
Nasdaq 9,388.9 +31.8
HSI 28,258.3 -537.6
HSCEI 11,129.6 -201.9
Jakarta 6,244.9 -0.1
Nikkei 225 23,889.3 -194.2
SSE Comp 3,071.6 -24.2
Shanghai A 3,218.5 -25.4
Shanghai B 258.3 -2.3
PSE Comp 0.0
KOSPI 2,249.0 -13.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

AVROBIO INC AVROBIO
Updated on 17 Jan 2020 (End of trading day)
Last (USD): 22.780 Change: +1.990 High: 22.980 Remarks: -
Change (%): +9.57 Low: 20.950
Open 20.950 Yesterday's Close 20.790000000000003
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 235,071 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -1.53480 Trailing EPS (USD) e -2.09435 NAV (USD) b 6.5290
PE a - Trailing PE f - Price / NAV b 3.4890
Dividend (USD) d - Cash In Hand (USD) g 6.5164 Issued & Paid-up Shares c 31,668,000
Dividend Yield (%) d - Price / Cash In Hand g 3.496 Treasury Shares h 61,013
Beta - 75 Daysi 0.409 R-Squared - 75 Days(%)i 0.45 Market Cap (M) 721.397
Beta - 500 Daysi -0.373 R-Squared - 500 Days (%)i 0.60 Enterprise Value (M) 515.035
Piotroski F Score 3 Exchange Code AVRO Par Value ( $ ) n.a.
52 Weeks Volatility (%) 91.18 Free Float (%) 71.0
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 11 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 11 Nov 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference AVROBIO INC NASDAQ 721.397 - - 3.4890 -
Industry Biotechnology NASDAQ 2,423.944 408.251 - 6.0398 0.727
Local Peer AMGEN INC NASDAQ 143,489.494 17.094 17.787 13.1317 2.317
Local Peer GILEAD SCIENCES INC NASDAQ 79,679.147 14.607 29.588 3.8672 3.668
Local Peer VERTEX PHARMACEUTICAL NASDAQ 60,643.685 28.928 28.288 11.5437 -
Local Peer BIOGEN INC NASDAQ 51,516.191 11.627 9.548 3.6808 -
Local Peer ILLUMINA INC NASDAQ 47,733.840 57.789 49.058 10.7533 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 42,374.657 17.335 19.762 4.0340 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,065.632 323.010 17.048 2.4178 -
Local Peer SEATTLE GENETICS INC NASDAQ 18,681.074 - - 10.4973 -
Local Peer INCYTE CORPORATION NASDAQ 17,339.459 158.362 42.817 7.1576 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,855.499 - - 5.1573 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 14,724.029 - 47.442 5.3271 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 13,247.242 - - 8.2430 -
Other Local Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), REPLIGEN CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), VIELA BIO INC (NASDAQ), ARVINAS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), INSMED INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), VERACYTE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEXTCURE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), OPKO HEALTH INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), RADIUS HEALTH INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), OMEROS CORP (NASDAQ), NANTKWEST INC (NASDAQ), CYTOKINETICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), IMMUNOGEN INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AGENUS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CABALETTA BIO INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), COMPUGEN (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PERSONALIS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), IVERIC BIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GERON CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), KAMADA (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XOMA CORP (NASDAQ), GLYCOMIMETICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CHIASMA INC (NASDAQ), IMV INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATHERSYS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ARAVIVE INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), NOVAVAX INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SAVARA INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), ADURO BIOTECH INC (NASDAQ), OTONOMY INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), SESEN BIO INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), COHBAR INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), SYNLOGIC INC (NASDAQ), INFLARX N V (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), TREVENA INC (NASDAQ), EQUILLIUM INC (NASDAQ), VERMILLION INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ADVAXIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), RESTORBIO INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ZAFGEN INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), ATYR PHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), VAXART INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRECIPIO INC (NASDAQ), SENESTECH INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), TROVAGENE INC (NASDAQ), OPGEN INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ)
Global Peer CSL ASX 137,727.155 51.335 51.335 18.4050 0.874
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,953.692 88.461 26.101 5.8875 0.678
Global Peer SINO BIOPHARM HKEx 151,866.775 14.173 14.710 4.5227 0.606
Global Peer WUXI BIO HKEx 135,461.602 181.362 141.784 13.9441 -
Global Peer BEIGENE HKEx 104,677.650 - - 10.4443 -
Global Peer GENSCRIPT BIO HKEx 34,633.468 208.277 - 9.7667 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer 3SBIO HKEx 28,244.466 18.671 22.726 2.7838 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,868.229 45.745 667.030 2.7712 -
Other Global Peers HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), MYOVANT SCIENCES LTD (NYSE), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD (ASX), VIVA BIOTECH (HKEx), MESOBLAST LTD (ASX), ASCENTAGE-B (HKEx), KADMON HLDGS INC (NYSE), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ESSEX BIO-TECH (HKEx), ASCLETIS-B (HKEx), LEE'S PHARM (HKEx), NEXT SCIENCE LTD (ASX), PFENEX INC (NYSE American), DPHARMA (Bursa), TELIX PHARMACEUTIC (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BBI LIFE SCI (HKEx), NANOVIRICIDES INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), UNI-BIO GROUP (HKEx), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), LINEAGE CELL THERAPEUTICS INC (NYSE American), 22ND CENTURY GROUP INC (NYSE American), IMUGENE LIMITED (ASX), PALATIN TECHNOLOGIES INC (NYSE American), CEL-SCI CORP (NYSE American), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), BIOSINO BIO-TEC (HKEx), INVEX THERAPEUTICS LTD NPV (ASX), ANTEOTECH LIMITED (ASX), MEMPHASYS LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), BIONOMICS LTD (ASX), BIOTRON (ASX), REGENT PACIFIC (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), ACTINOGEN MEDICAL LTD (ASX), TALI DIGITAL LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), ORAGENICS INC (NYSE American), EXTRAWELL PHAR (HKEx), ACTINIUM PHARMACEUTICALS INC (NYSE American), IBIO INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), PATRYS LIMITED (ASX), REGENEUS LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ADALTA LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ANATARA LIFESCIENCES LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), SIENNA CANCER DIAGNOSTICS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BIOXYNE LIMITED (ASX), QT Vascular (SGX), HAO WEN HLDGS (HKEx), MEDIBIO LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), AIM IMMUNOTECH INC (NYSE American), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+2.930
+14.76 %
10 Days -+2.280
+11.12 %
20 Days -+2.790
+13.96 %
Medium Term Return 3 Months -+8.980
+65.07 %
6 Months -+0.790
+3.59 %
1 Year -+9.420
+70.51 %
Annualised Return Annualised --
+70.51 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 11.845 - 28.520 Change From 1 Year Low +10.935 % Change From 1 Year Low (%) +92.32
Change From 1 Year High -5.740 % Change From 1 Year High (%) -20.13
2 Years Range 11.845 - 53.700 Change From 2 Years Low +10.935 % Change From 2 Years Low (%) +92.32
Change From 2 Years High -30.920 % Change From 2 Years High (%) -57.58
5 Years Range 11.845 - 53.700 Change From 5 Years Low +10.935 % Change From 5 Years Low (%) +92.32
Change From 5 Years High -30.920 % Change From 5 Years High (%) -57.58
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.

Historical Price Data

Date Open High Low Close Volume VWAP
17 Jan 2020 20.950 22.980 20.950 22.780 235,071 -
16 Jan 2020 20.060 20.850 19.855 20.790 128,799 -
15 Jan 2020 18.560 19.950 18.460 19.830 100,416 -
14 Jan 2020 17.750 18.850 17.070 18.450 169,542 -
13 Jan 2020 19.900 19.900 17.810 17.970 141,997 -
10 Jan 2020 20.380 20.910 19.710 19.850 195,557 -
09 Jan 2020 20.610 21.000 20.270 20.590 52,471 -
08 Jan 2020 20.210 20.970 19.980 20.490 97,110 -
07 Jan 2020 20.700 21.760 20.030 20.140 190,091 -
06 Jan 2020 20.310 20.800 20.040 20.680 95,593 -
03 Jan 2020 20.300 20.750 20.170 20.500 87,646 -
02 Jan 2020 20.340 20.870 19.860 20.610 120,598 -
31 Dec 2019 20.000 20.595 19.850 20.130 97,840 -
30 Dec 2019 19.590 20.250 19.220 20.050 142,006 -
27 Dec 2019 19.680 19.815 18.740 19.580 255,067 -
26 Dec 2019 20.330 20.400 19.750 19.790 125,941 -
24 Dec 2019 20.310 20.760 19.450 20.290 223,363 -
23 Dec 2019 19.990 20.390 19.510 20.290 263,409 -
20 Dec 2019 20.290 20.450 19.490 19.990 366,826 -
19 Dec 2019 20.430 20.570 19.560 20.080 249,326 -
18 Dec 2019 20.540 20.770 19.415 20.080 375,480 -
17 Dec 2019 21.740 21.740 20.260 20.670 277,389 -
Summary
Current 2 Weeks
(06 Jan 2020 to 17 Jan 2020)
20.310 22.980 17.070 22.780 1,406,647 -
Previous 2 Weeks
(19 Dec 2019 to 03 Jan 2020)
20.430 22.980 17.070 20.500 1,932,022 -
4 Weeks from
(20 Nov 2019 to 18 Dec 2019)
13.470 22.980 13.470 20.080 5,350,763 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.